Arrowhead Completes Zodasiran Phase 3 Enrollment; Pipeline Depth Grows but Near-Term Thesis Untouched

What happened

Arrowhead Pharmaceuticals has completed enrollment in the global Phase 3 YOSEMITE study of zodasiran for homozygous familial hypercholesterolemia (HoFH), adding a wholly-owned cardiometabolic asset to its late-stage pipeline. While this milestone reinforces the company’s ability to execute across multiple RNAi programs, zodasiran remains a longer-term opportunity relative to the dominant near-term drivers. The investment narrative is still overwhelmingly anchored on REDEMPLO’s commercialization and the pivotal severe hypertriglyceridemia (sHTG) readout expected in Q3 2026. The current stock price already embeds significant pipeline optionality, so incremental progress on zodasiran is unlikely to alter market sentiment markedly. Consequently, the WAIT rating and focus on REDEMPLO net sales and sHTG timelines remain intact.

Implication

Arrowhead’s completion of enrollment for zodasiran in HoFH underscores the company’s ability to advance multiple wholly-owned cardiometabolic programs. However, this milestone is a relatively distant catalyst, with data and potential approval likely years away. The investment case remains tethered to REDEMPLO’s early commercial performance and the pivotal sHTG readout, which will determine near-term valuation. While pipeline breadth supports long-term platform value, the current stock price already discounts a high probability of success across these assets. Investors should prioritize monitoring REDEMPLO net sales and sHTG timelines over incremental pipeline updates.

Thesis delta

No material shift in the investment thesis. Zodasiran progress adds pipeline diversification but does not affect the critical near-term checkpoints: REDEMPLO net sales disclosure and the Q3 2026 sHTG readout. The rating remains WAIT, with focus on commercialization execution.